source
- FDA review flags limited efficacy of Revolution's pancreatic cancer drug Rasonque, shares drop 6%Shares of Revolution Medicines fell about 6% after the Food and Drug Administration released review documents that suggest its pancreatic cancer therapy Rasonque may not work as well in all patient…
- Biotech Index Retraces Gains as Weak Trial Data and Market Fears WeighBioPharma Dive’s latest data‑visualization piece examines why biotech stocks have slipped recently and highlights the rapid pace of startup acquisitions this year. The XBI index, a barometer for b…